Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Aron Goldhirsch, W. C. Wood, Alan S. Coates et al. · Annals of Oncology · 2011 · 3.9K citations · Full text

Medicine, Oncology, Breast Oncology +16

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

David N. Krag, Stewart Anderson, Thomas B. Julian et al. · The Lancet Oncology · 2010 · 1.9K citations · Full text

Medicine, Oncology, Surgery +17

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

Bernard Fisher, A Brown, E.P. Mamounas et al. · Journal of Clinical Oncology · 1997 · 1.8K citations

Medicine, Oncology, Surgery +17

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

Thorsten Kuehn, Ingo Bauerfeind, Tanja Fehm et al. · The Lancet Oncology · 2013 · 1.5K citations

Medicine, Oncology, Surgery +17